Costo per responder di upadacitinib e abatacept nel trattamento dell’artrite reumatoide da moderata a grave in Italia

PURPOSE: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy. METHODS: The clinical efficacy was assessed based on SELECT-CHOI...

Descripción completa

Detalles Bibliográficos
Autores principales: Caporali, Roberto, Ravasio, Roberto, Raimondo, Paola, Salaffi, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616195/
https://www.ncbi.nlm.nih.gov/pubmed/36627881
http://dx.doi.org/10.33393/grhta.2021.2267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616195/
https://www.ncbi.nlm.nih.gov/pubmed/36627881
http://dx.doi.org/10.33393/grhta.2021.2267

Ejemplares similares